Revenue from operations was at Rs 1,255.02 crore for the quarter ended 31 March 2022 as against Rs 1,095.54 crore during the same period in the previous year, registering a growth of 14.56%. The drug makers profit before tax surged 44.49% to Rs 292.30 crore in Q4 FY22 from Rs 201.88 crore in Q4 FY21. On full year basis, the company reported a 15.64% increase in net profit to Rs 798.70 crore on a 14.14% declined in net sales to Rs 4,919.27 crore in FY22 over FY21. Meanwhile, the board of directors of the company has recommended payment of final dividend of Rs 145 and a special dividend of Rs 130 per equity share, for the financial year ended 31 March 2022. Abbott India has a portfolio of science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals. Powered by Capital Market - Live News
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.